Form 4: Beta Bionics CPO Sells Shares Under 10b5-1 Plan

Beta Bionics' Chief Product Officer, Mike Mensinger, sold 2,200 shares of common stock for a weighted average price of $30.1005 per share under a pre-arranged 10b5-1 plan.

Summary

• Mike Mensinger, Chief Product Officer of Beta Bionics, Inc. (BBNX), reported a sale of common stock.
• The transaction involved the disposition of 2,200 shares of common stock.
• The shares were sold at a weighted average price of $30.1005 per share, with prices ranging from $30.00 to $30.13.
• The sale was executed on January 6, 2026.
• This transaction was conducted pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.
• Following this transaction, Mr. Mensinger beneficially owns 80,752 shares of Beta Bionics common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a pre-scheduled insider stock sale under a Rule 10b5-1 plan, which is a routine disclosure and does not inherently convey strong positive or negative sentiment regarding the company's operational performance or future prospects.

Positives

• The insider sale was conducted under a pre-arranged Rule 10b5-1 Plan, indicating it was scheduled in advance and not a reaction to new material non-public information.

Negatives

• An insider, the Chief Product Officer, reduced their direct beneficial ownership by 2,200 shares.

Future Outlook

NA

Industry Context

This filing reports a routine insider transaction and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may view the insider sale as a routine diversification of holdings, especially given the pre-arranged 10b5-1 plan, which mitigates concerns about the timing of the sale.

Key Dates

Recommendation

The reported insider sale by the Chief Product Officer was executed under a pre-arranged Rule 10b5-1 plan, indicating it was scheduled in advance and not a reaction to new material non-public information. The transaction size is not exceptionally large relative to the insider's remaining holdings. Therefore, this event alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, as it is a routine disclosure rather than a signal of significant operational or strategic shifts.

Keywords

Beta Bionics, BBNX, Insider Trading, Form 4, Stock Sale, Chief Product Officer, Mike Mensinger, 10b5-1 Plan, Equity Transaction